Some bladder cancer patients benefit from Roche therapy
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Chicago
A NEWLY approved immunotherapy from Roche Holding proved effective as an initial treatment for some patients with advanced bladder cancer, according to data presented on Sunday.
Results of the mid-stage trial could help make the case that the drug, Tecentriq, should become the first option therapy of choice for patients with metastatic bladder cancer, according to a researcher leading the study.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Richard Eu on how core values, customers keep Singapore’s TCM chain Eu Yan Sang relevant
Aiming at China, Malaysia puts new restrictions on electric cars
Higher costs, lower returns: Why are Singaporeans still betting on real estate?
Vietnam formalises new state leadership, redefining ‘four pillars’ power balance
